Compare Ascendis Pharma A/S (ASND) vs Toronto-Dominion Bank (TD) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

TD stock trades at $120.53, up 0.65% with a bullish technical signal and strong analyst consensus. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.71. Revenue grew to $61.28B in 2025 with a robust 23.38% net income margin, though cash flow from operations was negative. The stock trades at a P/E of 20.08 and P/B of 2.51, with a consensus price target of $153.00 representing 27% upside potential.

TD presents a compelling investment case with strong profitability metrics, consistent earnings beats, and positive analyst sentiment. Key risks include volatile operating cash flows, rising debt-to-asset ratios, and economic sensitivity. The current valuation appears reasonable relative to growth prospects, supported by institutional confidence and dividend stability. Upside potential exists if the company maintains its earnings momentum and executes on operational improvements.